{"id":"rivaroxaban-10-milligram-oral-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Intracranial hemorrhage"},{"rate":null,"effect":"Syncope"}]},"_chembl":{"chemblId":"CHEMBL198362","moleculeType":"Small molecule","molecularWeight":"435.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rivaroxaban selectively inhibits Factor Xa, a serine protease central to both the intrinsic and extrinsic pathways of the coagulation cascade. By blocking Factor Xa, the drug prevents the conversion of prothrombin to thrombin, thereby reducing thrombin-mediated fibrin clot formation. This anticoagulant effect is used to prevent and treat thrombotic events.","oneSentence":"Rivaroxaban is a direct Factor Xa inhibitor that blocks a key enzyme in the blood coagulation cascade, preventing thrombin generation and clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:27.355Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of deep vein thrombosis and pulmonary embolism following hip or knee replacement surgery"},{"name":"Treatment of deep vein thrombosis and pulmonary embolism"},{"name":"Stroke prevention in patients with atrial fibrillation"},{"name":"Acute coronary syndrome"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xarelto"],"phase":"marketed","status":"active","brandName":"Rivaroxaban 10 milligram Oral Tablet","genericName":"Rivaroxaban 10 milligram Oral Tablet","companyName":"Florida Orthopaedic Institute","companyId":"florida-orthopaedic-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivaroxaban is a direct Factor Xa inhibitor that blocks a key enzyme in the blood coagulation cascade, preventing thrombin generation and clot formation. Used for Prophylaxis of deep vein thrombosis and pulmonary embolism following hip or knee replacement surgery, Treatment of deep vein thrombosis and pulmonary embolism, Stroke prevention in patients with atrial fibrillation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}